Effect of SAHA on sickle transgenic mice in vivo. Three-day pretreatment with SAHA diminished both VCAM (A) and TF (B) in the NY1DD mouse at air and after H/R. (A) *P < .001; **P < .001. (B) *P = .017. For panels A and B, the number of animals for bars left to right was 4, 5, 4, and 5, respectively. (C) In post-H/R S+S^Antilles sickle animals, SAHA inhibits stasis measured at 1 hour and 4 hours of reoxygenation. with P = .006 for both (#). Number of observations was 4 animals and 236 venules in the vehicle-treated group, and 4 animals and 245 venules in the SAHA-treated group. Overall, these data demonstrate that the clinically approved analog, SAHA, exhibits the same spectrum of effects as TSA. Error bars show SD (A-B) or SE (C).